Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (100)

Advertisement

Research Article Free access | 10.1172/JCI110659

Protective Role of Superoxide Dismutase against Diabetogenic Drugs

Samuel E. Gandy, Maria G. Buse, and Rosalie K. Crouch

Department of Biochemistry, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Ophthalmology, Medical University of South Carolina, Charleston, South Carolina 29425

Find articles by Gandy, S. in: PubMed | Google Scholar

Department of Biochemistry, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Ophthalmology, Medical University of South Carolina, Charleston, South Carolina 29425

Find articles by Buse, M. in: PubMed | Google Scholar

Department of Biochemistry, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425

Department of Ophthalmology, Medical University of South Carolina, Charleston, South Carolina 29425

Find articles by Crouch, R. in: PubMed | Google Scholar

Published September 1, 1982 - More info

Published in Volume 70, Issue 3 on September 1, 1982
J Clin Invest. 1982;70(3):650–658. https://doi.org/10.1172/JCI110659.
© 1982 The American Society for Clinical Investigation
Published September 1, 1982 - Version history
View PDF
Abstract

Copper-zinc superoxide dismutase (SOD) is present in relatively high concentrations in the β-cells of human islets. The activity of the extracted enzyme is partially inhibited upon incubation with the diabetogenic drugs alloxan, streptozotocin, or Vacor. The role of this enzyme in protecting β-cells against chemically induced diabetes was further investigated.

Incubation of intact canine islets with alloxan (0.2 mg/ml) and 4 mM glucose decreased the insulin secretory response by 87% during subsequent exposure to 28 mM glucose. Concomitantly the SOD-specific activity (units of enzyme activity per milligram immunoreactive SOD) decreased 50% in alloxan-exposed islets. When islets were protected from alloxan toxicity by including 28 mM glucose with alloxan, the insulin secretory response and SOD specific activity remained identical to controls. Thus, SOD specific activity correlates with maintenance of β-cell function.

To test the effectiveness of SOD against streptozotocin in vitro, canine islets were incubated 10 min with or without streptozotocin (0.1 mg/ml) with 4 mM glucose; their functional integrity was tested subsequently as the insulin secretory response to 28 mM glucose. Exposure to streptozotocin alone decreased the response by 70%; inclusion of SOD (1.5 mg/ml) before and during exposure to streptozotocin completely prevented this effect. Cyanide-inactivated SOD was not effective.

The potential of SOD to prevent streptozotocin-induced diabetes was tested in rats in vivo. SOD injected 10 s or 50 min before streptozotocin prevented or significantly attenuated diabetes. Injection of SOD and streptozotocin simultaneously was much less effective, and cyanide-inactivated SOD was ineffective. No protection was afforded by injection of SOD 12 or 24 h before streptozotocin.

Our results support hypotheses that (a) oxygen radicals mediate the β-cell toxicity of both alloxan and streptozotocin, and (b) β-cells may be particularly vulnerable to oxygen radical damage.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 650
page 650
icon of scanned page 651
page 651
icon of scanned page 652
page 652
icon of scanned page 653
page 653
icon of scanned page 654
page 654
icon of scanned page 655
page 655
icon of scanned page 656
page 656
icon of scanned page 657
page 657
icon of scanned page 658
page 658
Version history
  • Version 1 (September 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (100)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts